Study name |
Study type |
Year |
Country |
N |
Age (years) (mean ± SD) |
Male |
Hypertension |
Diabetes |
Hyperlipidemia |
Atrial fibrillation |
Coronary artery disease |
Heart Failure |
Left
ventricular ejection fraction (%) |
Anti-arrhythmic drugs |
Other QT prolonging drugs |
Monomorphic ventricular
tachycardia |
Saleh et al |
Prospective |
2020 |
USA |
201 |
58.5 ± 9.1 |
115 |
121 |
65 |
84 |
14 |
23 |
15 |
61.9±5.7 |
3 |
81 |
8 |
Chang et al |
Prospective |
2020 |
USA |
117 |
60.2±14.9 |
70 |
61 |
33 |
NR |
NR |
6 |
1 |
NR |
NR |
40 |
2 |
Bessiere et al |
Retrospective |
2020 |
France |
40 |
68 (IQR 58-74)
(median) |
32 |
23 |
16 |
NR |
NR |
NR |
NR |
NR |
NR |
20 |
0 |
Mercuro et al |
Retrospective |
2020 |
USA |
90 |
60.1±16.1 |
46 |
48 |
26 |
NR |
12 |
10 |
9 |
NR |
NR |
66 |
0 |